CGP 41251 is primarily recognized for its role as a protein kinase inhibitor, particularly targeting PKC (protein kinase C). Its applications are largely centered around research in cancer therapy, where it is studied for its potential to inhibit tumor growth by interfering with signaling pathways that promote cell proliferation and survival. By blocking PKC activity, CGP 41251 may help in reducing the progression of certain cancers, making it a valuable compound in preclinical studies. Additionally, it has been explored in the context of inflammation and immune response modulation, as PKC is involved in various cellular processes linked to these conditions. Its use in these areas contributes to a better understanding of disease mechanisms and the development of targeted therapeutic strategies.